Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina
Therapeutic Apheresis and Dialysis · 2026
DOI: 10.1111/1744-9987.14230 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Therapeutic Apheresis and Dialysis, 2026. Verfasst von Daniela Wojtowicz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hospital El Cruce, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Hyperparathyroidism, Secondary, Renal Dialysis, Peptides, Calcimimetic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Secondary hyperparathyroidism (sHPT) is a common complication in patients with chronic kidney disease (CKD). Recently, etelcalcetide (EC), an intravenous calcimimetic, has been introduced as a treatment. We evaluated the efficacy of EC in treating sHPT.
Methods
We conducted a multicenter, observational, retrospective study involving hemodialysis patients with sHPT, treated for at least 3 months with EC. We analyzed baseline and follow‐up values of intact parathyroid hormone (iPTH), calcium (Ca), phosphate (P), and alkaline phosphatase (ALP). Age, sex, time on dialysis, dialysate calcium concentration, and use of active vitamin D and phosphate binders were also recorded. Patients were divided into those receiving EC as de novo or after at least 3 months of cinacalcet treatment, and according to sHPT severity: PTH 1000 pg/mL.
Results
The study included 196 patients. Mean age was 52 ± 15 years; 52.3% were male. Median time on hemodialysis was 46.5 (20–72) months. Significant reductions were observed in baseline iPTH (1053 pg/mL), Ca (8.7 mg/dL), and P (5.7 mg/dL) over 2 years ( p < 0.0001), while ALP levels remained stable. iPTH reduction >30% was achieved in 37.5%, 64%, 66.7%, and 62.5% of patients at 3, 6, 12, and 24 months, respectively. EC was administered as initial treatment in 53% of patients, while 47% were switched from cinacalcet. Significantly iPTH reduction was observed in both groups. Greater reductions were noted in patients with initial PTH >1000 pg/mL ( p = 0.009). Two patients discontinued due to severe hypocalcemia.
Conclusions
EC effectively lowered iPTH and P levels, with a sustained effect over 2 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital El Cruce, Buenos Aires, Argentina.
- CEMIC, Buenos Aires, Argentina.
- Hospital Británico, Buenos Aires, Argentina.
- Instituto de Diagnostico e Investigaciones Metabólicas (IDIM), Buenos Aires, Argentina.
- Hospital Padilla, Tucumán, Argentina.
- Hospital Castro Rendon, Neuquén, Argentina.
ORCID-Profile: Daniela Wojtowicz, Gustavo Laham, Mariano Forrester, Elisa Del Valle, Adriana Peñalba, Graciela Filannino, Andrea Sammartino, Cecilia Mengarelli, Guillermo Rosa-Diez, Armando Luis Negri
Zitieren
APA
Wojtowicz, D., Laham, G., Forrester, M., Del Valle, E., Peñalba, A., Filannino, G., Sammartino, A., Mengarelli, C., Rosa-Diez, G., & Negri, A. L. (2026). Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14230
Vancouver
Wojtowicz D, Laham G, Forrester M, Del Valle E, Peñalba A, Filannino G, et al. Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina. Therapeutic Apheresis and Dialysis. 2026. doi:10.1111/1744-9987.14230
BibTeX
@article{Wojtowicz2026,
author = {Wojtowicz, Daniela and Laham, Gustavo and Forrester, Mariano and Del Valle, Elisa and Peñalba, Adriana and Filannino, Graciela and Sammartino, Andrea and Mengarelli, Cecilia and Rosa-Diez, Guillermo and Negri, Armando Luis},
title = {Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina},
journal = {Therapeutic Apheresis and Dialysis},
year = {2026},
doi = {10.1111/1744-9987.14230}
}
EUVIMED